ODM-201 is safe and active in metastatic castration-resistant prostate cancer
- PMID: 25185192
- DOI: 10.1158/2159-8290.CD-RW2014-150
ODM-201 is safe and active in metastatic castration-resistant prostate cancer
Abstract
The next-generation AR inhibitor ODM-201 is tolerable and induces PSA responses in metastatic CRPC.
©2014 American Association for Cancer Research.
Comment on
-
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25. Lancet Oncol. 2014. PMID: 24974051 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous